Serum Inflammation Markers in Tuberculosis

• Published in: Acta medica martiniana Vol. 20; no. 3; pp. 103 - 113
• Main Authors: Kusnir, P, Dohal, M, Porvaznik, I, Mokry, J.
• Format: Journal Article
• Language: English
• Published: Sciendo 01-12-2020
• Subjects: crp; granzyme b; inflammatory markers; sicam-1; slag-3; stnfr i, ii; supar; tuberculosis
• ISSN: 1335-8421; 1335-8421
• DOI: 10.2478/acm-2020-0012

Tuberculosis remains one of the leading infectious cause of death in the world. The goals of screening are to detect active tuberculosis early enough and to identify individuals eligible for preventive therapy to reduce a po tential co-infection by tuberculosis. Plasma/serum screening for selected potential biomarkers could represent a suitable method of tuberculosis diagnosis and treatment outcome. Furthermore, monitoring of tuberculosis treatment is crucial to clinical decision-making and besides the plasmatic concentration of administered antituberculosis drugs, the biomarkers appear to play a significant role in the estimation of the real therapeutical impact.
The current standard remains focused on culture conversion, especially two-month culture status, which has a relatively low sensitivity. Identification of non-sputum-based biomarkers of the treatment respond would be beneficial for individual monitoring of tuberculosis patients.
This mini-review describes several serological/plasmatic markers that can be analyzed by simple immunoassays as ELISA method, e.g. C-reactive protein, soluble intercellular adhesion molecule-1, soluble urokinase plasminogen activator receptor, soluble lymphocyte activation gene-3, granzyme B and soluble tumor necrosis factor receptor one and two as reliable enough as an indicator of successful treatment of tuberculosis.